Literature DB >> 29502892

Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.

Jun Li1, Zhizhong Wang2, Harry J M Groen3, Jiuzhou Zhao1, Peng Wang4, Cuiyun Zhang5, Ke Yang1, Yongjun Guo1, Jie Ma6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29502892     DOI： 10.1016/j.lungcan.2018.02.016

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  5 in total

1.  Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report.

Authors:  Yan Zhang; Bixiu He; Dongbo Zhou; Min Li; Chengping Hu
Journal:  Onco Targets Ther       Date:  2018-12-18       Impact factor: 4.147

2.  Successful Treatment of Afatinib Reversing Epidermal Growth Factor Receptor Exon19Deletion/G724S Mutation Resistance Guided by Protein-Drug Docking.

Authors:  Nian Yu; Yinghui Xu; Xu Wang; Chao Sun; Shi Qiu; Ye Guo; Miao Bai; Yanxin Huang; Kewei Ma
Journal:  Oncologist       Date:  2021-09-12

3.  Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S.

Authors:  Yang Wei; Benyuan Jiang; Shulin Liu; Zhonghan Zhang; Wenfeng Fang; Yunpeng Yang; Xin Li; Jingyi Zhao; Hongyun Zhao
Journal:  JTO Clin Res Rep       Date:  2021-05-24

4.  Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status.

Authors:  Jun Liao; Yihua Huang; Jiadi Gan; Lanlan Pang; Wael A S Ali; Yunpeng Yang; Likun Chen; Li Zhang; Wenfeng Fang
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

5.  Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review.

Authors:  Cuicui Zhang; Li Lin; Ran Zuo; Yajie Wang; Peng Chen
Journal:  Thorac Cancer       Date:  2020-08-09       Impact factor: 3.500
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.